688382.SHG InventisBio Co. Ltd. A
- Market cap
- CNY 8.03B
- P/E
- -
- P/B
- 5.28x
- ROE
- -19.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688382.SHG undervalued?
Graham numberThe Graham number of InventisBio Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InventisBio Co. Ltd. A fundamental analysis
No fundamental analysis for InventisBio Co. Ltd. A yet.
InventisBio Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InventisBio Co. Ltd. A
InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D…
Full company profileInventisBio Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InventisBio Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 186M | 169M | 37.3M | 107M |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | 186M | 165M | 32.3M | 101M |
| Operating Income | - | 0.00 | -358M | -519M | -315M | -264M | -330M | -290M |
| EBITDA | - | - | - | -467M | -265M | -221M | -301M | -274M |
| Net Income | - | -1.05B | -358M | -483M | -284M | -240M | -317M | -274M |
| EPS | - | -2.29 | -0.78 | -0.84 | -0.49 | -0.42 | -0.55 | -0.47 |
| Balance Sheet | ||||||||
| Total Assets | - | 1.07B | 800M | 2.35B | 2.16B | 1.92B | 1.70B | 1.52B |
| Total Liabilities | - | 61.5M | 115M | 133M | 165M | 110M | 168M | 111M |
| Shareholders' Equity | - | 1.01B | 685M | 2.21B | 2.00B | 1.81B | 1.54B | 1.41B |
| Cash & Short-term Investments | - | 1.03B | 724M | 2.24B | 1.92B | 1.59B | 1.38B | 1.17B |
| Cash Flow | ||||||||
| Operating Cash Flow | - | -197M | -252M | -477M | -308M | -242M | -155M | - |
| Capital Expenditure | 0.00 | 5.60M | 26.5M | 7.69M | 6.29M | 7.56M | 6.92M | 11.0M |
| Free Cash Flow | - | -197M | -279M | -485M | -314M | -250M | -162M | -387M |
| Ratios | ||||||||
| ROE | - | -104.3% | -52.2% | -21.8% | -14.2% | -13.3% | -20.6% | -19.4% |
| ROA | - | -98.3% | -44.7% | -20.6% | -13.1% | -12.5% | -18.6% | -18.0% |
| Net Profit Margin | - | - | - | - | -153.1% | -142.3% | -849.7% | -257.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
InventisBio Co. Ltd. A dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | CNY 183K | 0.00 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns InventisBio Co. Ltd. A
- Insiders 31.13%
- Institutions 21.65%
- Public & others 47.22%
- Shares outstanding 580M
- Free float 412M
InventisBio Co. Ltd. A company profile
- Company name
- InventisBio Co. Ltd. A
- Ticker
- 688382.SHG
- ISIN
- CNE100005Q22
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 182
- Fiscal year end
- December
- Address
- No.4, Libing Road, Shanghai, China, 201203
- Phone
- 86 21 5077 8527
- Website
- inventisbio.com
About InventisBio Co. Ltd. A
InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer. The company also develops D"2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout. In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma. InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.
InventisBio Co. Ltd. A management
5- Dr. Yaolin WangCEO & Chairman · born 1963
- Mr. Luwei ShiCFO, Chief Accountant & Director · born 1985
- Mr. Xing DaiDeputy GM & Director · born 1975
- Mr. Zhang LingDeputy GM & Chief Medical Officer · born 1964
- Mr. Yueheng JiangDeputy GM, Secretary & Director · born 1971